Table 6.
Plasma and liver malondialdehyde (MDA), superoxide dismutase (SOD) and glutathione peroxidase (GPx) activity after the six-week melatonin intervention.
| Group | C | D | L | M | H |
|---|---|---|---|---|---|
| Liver | |||||
| MDA (nmol/g tissue) | 91.2 ± 16.1 a | 127.2 ± 10.7 b | 93.1 ± 18.5 a | 95.4 ± 14.7 a | 84.4 ± 22.3 a |
| SOD (U/mg protein) | 2.18 ± 0.96 a | 1.12 ± 0.11 b | 1.43 ± 0.30 b,c | 1.52 ± 0.47 b,c | 1.75 ± 0.26 a,c |
| GPx (nmol/min/mg protein) | 5.60 ± 1.00 a | 3.79 ± 0.43 b | 4.04 ± 0.63 b | 4.16 ± 0.76 b | 4.03 ± 0.42 b |
| Plasma | |||||
| MDA (µM) | 31.1 ± 7.6 a | 66.7 ± 16.6 b | 58.3 ± 13.3 b,c | 45.3 ± 14.5 c | 47.3 ± 4.97 c |
All values are the mean ± SD (n = 8); a, b, c Values with different superscripts significantly differ between groups (p < 0.05); C, control group; D, diabetic group; L, low-dosage group (10 mg melatonin/kg of body weight (BW)); M, medium-dosage group (20 mg melatonin/kg of BW); and H, high-dosage group (50 mg melatonin/kg of BW).